Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 7, 2011

View Archived Issues

Phase I study assesses AstraZeneca chemokine CXCR2 receptor antagonist in healthy volunteers

Millennium Pharmaceuticals discloses updated results from ongoing phase I trial of MLN-9708

Novel chitosan-based antibacterial agent developed at Synedgen

Lundbeck synthesizes multiple metabotropic glutamate receptor modulators

BTG provides 6-month update

New biomarker panel predicts risk of adverse events in patients with chronic heart failure

Bavarian Nordic gains rights to NCI anticancer vaccine candidate

Shionogi presents new oxazolidinones with potent antibacterial activity in vitro and in vivo

Pharmalucia discloses new photosensitizing agents

Novel prostanoid DP1 receptor antagonist patented by Sanofi

X-BODY BioSciences partners with Tanabe Research Laboratories for antibody therapeutics

Lightlake announces plans for phase II trials of bulimia nervosa therapy

New PLK1 inhibitors developed

Pfizer licenses neratinib to Puma Biotechnology

Alexza Pharmaceuticals partners with Grupo Ferrer for Adasuve

New cross-linked multimeric proteins for Fabry's disease claimed by Protalix Biotherapeutics

Servier exercises option to acquire sole rights to high-impact Ampakine product

Biovest presents regulatory strategy for BiovaxID in follicular lymphoma

Theratechnologies discovers novel GRF peptide

Probiodrug reports novel glutaminyl-peptide cyclotransferase inhibitors

Enrollment complete in Peregrine phase II NSCLC trial

BioCancell recruits first patients in BC-819 pancreatic cancer study

Dynavax reports more data from phase III Heplisav study

Millennium withdraws sNDA for Velcade

FDA approves Lilly's Cialis for new indications

Metabolic Solutions Development receives NIH grant for MSDC-0602 program

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.